Etrasimod in Treatment of Ulcerative Colitis: A Comprehensive Review

TL;DR

This paper reviews treatment options for ulcerative colitis, focusing on Etrasimod, a new drug that modulates a specific receptor to manage the disease.

Contribution

The paper introduces Etrasimod as a novel S1PR modulator with potential for treating ulcerative colitis.

Findings

Current therapies for UC include 5-ASA, TNFi, anti-integrins, and JAK inhibitors.

Etrasimod is a promising S1PR modulator with molecular and clinical potential for UC treatment.

Abstract

Ulcerative colitis (UC) is a chronic, inflammatory disease of the colon. The unpredictable, systemic, and debilitating nature of UC puts disease management and patient monitoring at a pivotal point. Despite substantial development in pharmacotherapies for UC in recent years, a significant proportion of patients either fail to respond to treatment or lose their response over the course of the disease. The backbone of disease management in UC is 5-aminosalicylic acid (5-ASA), but patients unresponsive to 5-ASA or with severe disease require advanced therapies including tumor necrosis factor-alpha inhibitors (TNFi), anti-integrins, anti-interleukins and small molecule therapy, Janus kinase (JAK) inhibitors, and S1PR modulators. This review will briefly overview the current state of medical therapeutic options in UC, with further detailing the molecular and clinical aspects of Etrasimod, a sphingosine-1-phosphate receptor (S1PR) modulator.

Figures